Posted by Michael Wonder on 23 Jan 2024
Autolus Therapeutics announces acceptance of biologics license application for obecabtagene autoleucel as a potential treatment for relapsed/refractory adult B-cell acute lymphoblastic leukaemia
22 January 2024 - PDUFA goal date is 16 November 2024.
Autolus Therapeutics today announces that the US FDA has accepted its biologics license application for obecabtagene autoleucel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia.
